Large Outflow of Money Witnessed in BioMarin Pharmaceutical Inc.

Shares of BioMarin Pharmaceutical Inc. (BMRN) traded 0.96 points or 1.1% higher at $88.59.The total intraday money flow for the shares came in at a disappointing $(-6.82) million. The total upticks amounted to $23.61 million and the total downticks were approximately $30.43 million, with the up/down ratio of 0.78. On a different note, the shares have seen 2.35% price change during the week.In a block trade which occurred during the day, the stock had an inflow of $0.88 million in upticks and an outflow of $8.74 million in downticks. The up/down ratio for the block was found to be 0.1. The net money flow for the block transaction was $(-7.86) million.Block trades are executed by Investment Banking firms or Wealth Managers shifting positions or Day traders taking advantage of trading signals.

Shares of BioMarin Pharmaceutical Inc. rose by 5.65% in the last five trading days and 6.94% for the last 4 weeks. BioMarin Pharmaceutical Inc. is up 10.02% in the last 3-month period. Year-to-Date the stock performance stands at 6.94%. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) rose 1.1% or 0.96 points on Wednesday and made its way into the gainers of the day. After trading began at $87.79 the stock was seen hitting $89.1467 as a peak level and $87.445 as the lowest level. The stock ended up at $88.59. The daily volume was measured at 1,267,894 shares. The 52-week high of the share price is $102.49 and the 52-week low is $62.12. The company has a market cap of $15,236 million.

Company has reported several Insider transactions to the SEC, on Jan 27, 2017, Jean Jacques Bienaime (Chief Executive Officer) sold 10,000 shares at 84.22 per share price.On Jan 10, 2017, Daniel K Spiegelman (EVP, Chief Financial Officer) sold 5,000 shares at 90.00 per share price.On Nov 29, 2016, Henry J Fuchs (President, Worldwide R&D) sold 15,000 shares at 87.40 per share price.

BioMarin Pharmaceutical Last issued its quarterly earnings results on Oct 27, 2016. The company reported $0.02 EPS for the quarter, beating the analyst consensus estimate by $ 0.10. Analyst had a consensus of $-0.08. The company had revenue of $279.90 million for the quarter, compared to analysts expectations of $289.36 million. The companys revenue was up 34.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.60 EPS.

Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.BioMarin Pharmaceutical was Resumed by Credit Suisse to Outperform on Jan 23, 2017. BioMarin Pharmaceutical was Initiated by Gabelli & Co on Dec 8, 2016 to Buy, Price Target of the shares are set at $109.BioMarin Pharmaceutical was Downgraded by Piper Jaffray to Neutral on Nov 7, 2016.

BioMarin Pharmaceutical Inc. is a developer of carbohydrate enzyme therapies for debilitating, life-threatening, chronic genetic disorders and other diseases and conditions. The company completed a six-month evaluation of patients being treated with BioMarins lead product, BM101, for the treatment of mucopolysaccharidosis-I, or MPS-I. Patients were treated with BM101 as part of a pivotal clinical trial completed to determine the safety and efficacy of the drug in humans.


Share this post

Leave a Reply